Lupin on Monday said it has received a tentative approval from the US health regulator to market Dasatinib tablets, used to treat certain types of cancer, in America.
The company in partnership with Pharmascience Inc. has received approval from the US Food and Drug Administration (FDA) for Dasatinib tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, it said in a statement.
The Mumbai-based drug maker's product is a generic version of Bristol-Myers Squibb Company's Sprycel tablets.
As per IQVIA MAT data, Dasatinib tablets had an estimated annual sale of USD 1,569 million in the US.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Elon Musk's Neuralink Gets Go Ahead For Brain Chip Implant In 2nd Patient: Report Yoghurt May Help Reduce Risks Of Type 2 Diabetes - FDA Says Maharashtra Revokes Licence Of McDonald's Outlet After Action Over Cheese Nurse Raped, Killed On Way Home, Body Found 9 Days Later In UP "Don't Expect Anything From Me": Kolkata Hospital's New Principal Loses Cool This US City Has Been Declared America's Least Desirable, Survey Finds Trump To Hold Press Conference, His Campaign Adds Senior Advisers Left, BJP, Creating Unrest: Mamata Banerjee On Midnight Attack At Hospital 'Don't Club Us With Others,' Says Manipur's Thadou Tribe, Waits For Peace Plan Track Latest News Live on NDTV.com and get news updates from India and around the world.